ALPHARETTA, Ga., Aug. 11, 2016 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a de novo petition requesting Agency review and classification of the dermaPACE System for treating Diabetic Foot Ulcers (DFU) as a Class II device. Through the course of two […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone